Printer Friendly

NEW CIBA-GEIGY DRUG AVAILABLE FOR LIFE-THREATENING CANCER COMPLICATION

NEW CIBA-GEIGY DRUG AVAILABLE FOR LIFE-THREATENING CANCER COMPLICATION
 SUMMIT, N.J., Nov. 7 /PRNewswire/ -- The U.S. Food and Drug Administration last week cleared for marketing Aredia(TM) (pamidronate disodium for injection, for intravenous infusion), for the treatment of moderate or severe hypercalcemia of malignancy in patients with or without bone metastases. The new drug was developed by the pharmaceuticals division of CIBA-GEIGY Corporation.
 Hypercalcemia is an elevated concentration of calcium in the blood. Hypercalcemia of malignancy (HCM) is the most common metabolic complication of cancer and is potentially fatal. It most often occurs in patients with breast cancer, multiple myeloma, and cancer of the lung, prostate, kidney, head, or neck. Symptoms of HCM include lethargy, anorexia, nausea, dehydration, and bone pain. Aredia normalizes a patient's calcium level.
 Results from clinical studies show that Aredia normalizes serum calcium within seven days in 61 percent and 100 percent of patients receiving 60-mg and 90-mg doses, respectively.
 In addition, many patients receiving a single dose of Aredia continued to have normal corrected serum calcium levels or a partial response at day 14.
 Side effects of Aredia include mild, transient fever, infusion site reaction, asymptomatic hypophosphatemia (low blood phosphate level), and asymptomatic hypomagnesemia (low blood magnesium level).
 CIBA-GEIGY is a leading developer and manufacturer of pharmaceutical products. CIBA-GEIGY Corporation is a unit of CIBA-GEIGY Ltd., Basel, Switzerland.
 -0- 11/7/91
 /CONTACT: Doug Arbesfeld of CIBA-GEIGY, 908-277-5758, or Rori Reiner of GTFH Public Relations, 212-886-3108, for CIBA-GEIGY/ CO: CIBA-GEIGY Corporation ST: New Jersey IN: MTC SU: PDT SM-CK -- NY024 -- 2117 11/07/91 10:21 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 7, 1991
Words:263
Previous Article:FUJIFILM STARTS OPERATIONS AT VIDEOTAPE FACTORY IN GREENWOOD, S.C.
Next Article:HECHINGER COMPANY ANNOUNCES OCTOBER SALES
Topics:


Related Articles
NICOTINE SKIN PATCH AVAILABLE FOR SMOKING CESSATION
CIBA-GEIGY NAMES ROBINSON MANAGER OF EXTERNAL COMMUNICATIONS
Alex Krauer.
IMMUNOGEN, INC. NAMES ROBERT E. TELLIS VICE PRESIDENT OF CORPORATE DEVELOPMENT
FAST-ACTING, EFFECTIVE TREATMENT OPTION OFFERS NEW ALTERNATIVE FOR AMERICANS' PAIN RELIEF NEEDS
NEW DOSAGE STRENGTH FOR NITROGLYCERINE PATCH ANNOUNCED
ONCOGENE SCIENCE'S COLLABORATIVE PARTNER CIBA FILES IND FOR ORAL MUCOSITIS PRODUCT
NEW ESTROGEN PATCH OFFERS MENOPAUSAL WOMEN COMFORT AND FLEXIBLE DOSING
First Anti-Epileptic Drug in Extended Release Formulation Available to Patients Today; National Survey Documents Need

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters